14.2 Refractory Septic Shock & Adjunctive Therapies

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

14.2 Refractory Septic Shock & Adjunctive Therapies

Key Takeaways Explain This Topic AI

Refractory septic shock is defined by persistent tissue hypoperfusion and hemodynamic instability necessitating high-dose vasopressor support (typically norepinephrine >= 0.25-0.5 mcg/kg/min) and secondary agents despite adequate intravascular volume restoration.

Norepinephrine is the first-line vasopressor of choice; vasopressin should be added as a second-line agent at a non-titratable, fixed dose of 0.03 units/min to treat relative vasopressin deficiency, reduce catecholamine requirements, and lower tachyarrhythmia risk.

Third-line vasoactive options include adding epinephrine (with awareness of transient beta-2-mediated aerobic hyperlactatemia) or angiotensin II, while inotropic support with dobutamine is indicated for documented septic cardiomyopathy with persistent hypoperfusion.

SSC 2021 suggested hydrocortisone 200 mg/day for septic shock on norepinephrine >= 0.25 mcg/kg/min for >= 4 hours; SSC 2026 broadens this to a conditional suggestion of IV corticosteroids for adults with septic shock. ACTH stimulation testing is not used to select patients.

SSC 2026 suggests crystalloids alone over adding albumin and suggests against IV vitamin C; LOVIT (2022) showed more death or persistent organ dysfunction with vitamin C (44.5% vs. 38.5%).

Last updated: October 2026

Septic shock unresponsive to initial fluid resuscitation and moderate doses of first-line vasopressors represents a high-mortality clinical emergency. In this phase of critical illness, pathological vasodilation (vasoplegia), adrenergic receptor downregulation, intrinsic neurohormonal exhaustion, and myocardial depression conspire to produce refractory circulatory collapse. Managing this complex state requires a structured, evidence-based algorithm for vasoactive escalation alongside targeted adjunctive therapies.

Defining Refractory Septic Shock

While variable consensus thresholds exist in critical care literature, refractory septic shock is generally defined as:

Persistent tissue hypoperfusion and hemodynamic instability requiring high doses of first-line vasopressors (typically norepinephrine ≥ 0.25 to 0.5 mcg/kg/min \ge 0.25\text{ to }0.5\text{ mcg/kg/min} ≥ 0.25 to 0.5 mcg/kg/min ) along with secondary vasoactive agents to maintain a mean arterial pressure (MAP) ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg , despite adequate fluid loading.

Cellular Pathophysiology of Vasoplegia

Vasodilatory shock in sepsis is driven by four synergistic cellular mechanisms:

Inducible Nitric Oxide Synthase (iNOS) Overexpression: Massive inflammatory cytokine release (TNF- α \alpha α , IL- 1 β 1\beta 1 β , interferon- γ \gamma γ ) induces vascular endothelial and smooth muscle iNOS, generating pathological levels of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), forcing profound vascular smooth muscle relaxation.

ATP-Sensitive Potassium ( K ATP \text{K}_{\text{ATP}} K ATP ​ ) Channel Opening: Intracellular ATP depletion and severe lactic acidosis activate vascular K ATP \text{K}_{\text{ATP}} K ATP ​ channels, hyperpolarizing vascular smooth muscle cell membranes and preventing calcium entry through voltage-gated L-type calcium channels.

Adrenergic Receptor Desensitization: High circulating endogenous catecholamine levels promote beta-arrestin binding, G-protein uncoupling, and internalization of vascular α 1 \alpha_1 α 1 ​ -adrenergic receptors, resulting in pharmacological tolerance.

Neurohypophyseal Vasopressin Depletion: Depletion of pre-formed neurosecretory stores within the posterior pituitary gland leads to an absolute or relative vasopressin deficiency state within hours of shock onset.

Vasopressor Escalation Architecture

The Surviving Sepsis Campaign (2021 guideline, updated 2026) outlines a tiered hierarchy for vasoactive initiation and escalation: ┌────────────────────────────────────────┐

• │ First-Line Vasopressor: Norepinephrine │
• │ Titrate to 0.25-0.5 mcg/kg/min │
• └───────────────────┬────────────────────┘
• │
• MAP < 65 mmHg or Escalating Dose
• │
• ▼
• ┌────────────────────────────────────────┐
• │ Second-Line: Add Fixed-Dose Vasopressin│
• │ Fixed non-titratable 0.03 units/min │
• └───────────────────┬────────────────────┘
• │
• MAP Remains < 65 mmHg Despite Dual Therapy
• │
• ┌───────────────────┴───────────────────┐
• ▼ ▼
• Third-Line: Add Epinephrine Third-Line: Add Angiotensin II
• (0.05-0.5 mcg/kg/min) (1.25-20 ng/kg/min, ATHOS-3)
• │ │
• └───────────────────┬───────────────────┘
• │
• ┌─────────────────────────────┴─────────────────────────────┐
• │ Documented Myocardial Dysfunction or Persistent Hypoperfusion│
• └─────────────────────────────┬─────────────────────────────┘
• │
• ▼
• ┌────────────────────────────────────────┐
• │ Add Inotrope: Dobutamine │
• │ Titrate 2.5-20 mcg/kg/min │
• └────────────────────────────────────────┘
• 1. First-Line: Norepinephrine

Norepinephrine is the first-line vasopressor for septic shock: the 2026 SSC recommends it over dopamine, epinephrine, or selepressin (strong) and suggests it over vasopressin or angiotensin II as the first agent (conditional). Norepinephrine acts as a potent α 1 \alpha_1 α 1 ​ -adrenoceptor agonist, producing powerful peripheral vasoconstriction that increases systemic vascular resistance (SVR) and mean systemic filling pressure ( P msf P_{\text{msf}} P msf ​ ). It also possesses modest β 1 \beta_1 β 1 ​ -adrenergic activity, augmenting stroke volume and supporting heart rate without inducing excessive tachycardia.

Target MAP is 65 mmHg 65\text{ mmHg} 65 mmHg (strong recommendation), and the 2026 SSC suggests 60-65 mmHg for patients aged 65 or older . In SEPSISPAM (NEJM 2014), a higher target (80-85 mmHg) did not reduce mortality and increased atrial fibrillation; in its chronic hypertension subgroup, fewer patients needed renal replacement therapy, a hypothesis-generating finding that does not override the 65 mmHg starting target.

2. Second-Line: Vasopressin (AVP)

For septic shock on escalating doses of norepinephrine, the SSC suggests adding vasopressin (conditional recommendation); the 2021 guideline described the usual practice of adding it when norepinephrine reaches about 0.25 to 0.5 mcg/kg/min 0.25\text{ to }0.5\text{ mcg/kg/min} 0.25 to 0.5 mcg/kg/min , typically at a fixed dose of 0.03 units/min 0.03\text{ units/min} 0.03 units/min , rather than escalating norepinephrine indefinitely.

Mechanism: Vasopressin binds vascular V 1 a V_{1a} V 1 a ​ receptors coupled to the G q G_q G q ​ pathway, activating phospholipase C and releasing intracellular calcium to restore vascular tone independently of adrenergic receptors. It also directly closes vascular smooth muscle K ATP \text{K}_{\text{ATP}} K ATP ​ channels and downregulates iNOS expression.

Dosing Rules: Vasopressin is administered at a fixed, non-titratable infusion rate of 0.03 units/min 0.03\text{ units/min} 0.03 units/min (or 0.01 − 0.03 units/min 0.01-0.03\text{ units/min} 0.01 − 0.03 units/min ). It should NOT be titrated up and down like catecholamines. Infusion rates exceeding 0.03 − 0.04 units/min 0.03-0.04\text{ units/min} 0.03 − 0.04 units/min cause severe splanchnic vasoconstriction, mesenteric ischemia, coronary spasm, and peripheral digital necrosis.

Trial Evidence:

VASST Trial (NEJM 2008): In 778 septic shock patients, adding low-dose vasopressin spared norepinephrine requirements. While overall 28-day mortality was not significantly different, a pre-defined subgroup analysis of patients with less severe shock (norepinephrine < 15 mcg/min < 15\text{ mcg/min} < 15 mcg/min ) demonstrated a statistically significant survival benefit with vasopressin ( 26.5 % 26.5\% 26.5% vs. 35.7 % 35.7\% 35.7% , p = 0.05 p = 0.05 p = 0.05 ).

VANISH Trial (JAMA 2016): Evaluated early vasopressin versus norepinephrine. Vasopressin spared catecholamines and did not improve the primary outcome (kidney failure-free days); fewer survivors in the vasopressin arm received renal replacement therapy ( 25.4 % 25.4\% 25.4% vs. 35.3 % 35.3\% 35.3% ), a secondary finding. A 2018 meta-analysis (McIntyre et al., JAMA ) associated vasopressin added to catecholamines with less atrial fibrillation.

3. Third-Line Agents: Epinephrine and Angiotensin II

If shock persists despite norepinephrine and vasopressin:

Epinephrine: Acts across α 1 \alpha_1 α 1 ​ , β 1 \beta_1 β 1 ​ , and β 2 \beta_2 β 2 ​ receptors. Epinephrine can be added at 0.05 − 0.5 mcg/kg/min 0.05-0.5\text{ mcg/kg/min} 0.05 − 0.5 mcg/kg/min .

Note

Epinephrine frequently triggers transient aerobic hyperlactatemia via skeletal muscle β 2 \beta_2 β 2 ​ -adrenoceptor stimulation, which stimulates Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase and accelerates glycolysis faster than pyruvate dehydrogenase can process pyruvate. This benign lactate rise must not be mistaken for worsening tissue dysoxia when central venous oxygen saturation ( ScvO 2 \text{ScvO}_2 ScvO 2 ​ ) and urine output are improving.

Angiotensin II (Giapreza): Approved after ATHOS-3 (NEJM 2017) , in which adding angiotensin II to high-dose vasopressors raised MAP at 3 hours (primary outcome) and spared catecholamines. 28-day mortality was not significantly different (46% vs. 54%, p = 0.12 p = 0.12 p = 0.12 ); apparent benefit in patients needing renal replacement therapy or with high renin came from post hoc analyses. The SSC suggests norepinephrine over angiotensin II as the first-line agent, and angiotensin II remains an option for refractory vasodilatory shock.

2026 SSC escalation statements: For inadequate MAP despite norepinephrine and vasopressin, suggest adding epinephrine ; for septic shock with cardiac dysfunction, suggest either norepinephrine or epinephrine first; suggest against terlipressin and levosimendan, and suggest against beta-blockers as a treatment for septic shock; and there is insufficient evidence to recommend methylene blue or oral midodrine .

Vasoactive Agent Primary Receptor Affinities Hemodynamic Effects Standard Infusion Range Pivotal Trials & Evidence

Norepinephrine α 1 ≫ β 1 > β 2 \alpha_1 \gg \beta_1 > \beta_2 α 1 ​ ≫ β 1 ​ > β 2 ​ ↑ SVR \uparrow\text{SVR} ↑ SVR , ↑ MAP \uparrow\text{MAP} ↑ MAP , mild ↑ CO \uparrow\text{CO} ↑ CO , minimal tachycardia 0.02 − 1.0 + mcg/kg/min 0.02-1.0+\text{ mcg/kg/min} 0.02 − 1.0 + mcg/kg/min First-line vasopressor (SOAP II trial: lower arrhythmia and mortality vs. dopamine)

Vasopressin V 1 a ≫ V 2 V_{1a} \gg V_2 V 1 a ​ ≫ V 2 ​ ↑ SVR \uparrow\text{SVR} ↑ SVR , catecholamine sparing, preserves renal afferent tone Fixed 0.03 units/min 0.03\text{ units/min} 0.03 units/min VASST (possible benefit in less severe shock stratum), VANISH (less RRT use, secondary outcome)

Epinephrine α 1 = β 1 > β 2 \alpha_1 = \beta_1 > \beta_2 α 1 ​ = β 1 ​ > β 2 ​ ↑ SVR \uparrow\text{SVR} ↑ SVR , ↑ CO \uparrow\text{CO} ↑ CO , ↑ HR \uparrow\text{HR} ↑ HR , transient aerobic lactate rise 0.05 − 0.5 mcg/kg/min 0.05-0.5\text{ mcg/kg/min} 0.05 − 0.5 mcg/kg/min CATS trial (equivalent 28-day survival vs. norepinephrine + dobutamine)

Dobutamine β 1 > β 2 ≫ α 1 \beta_1 > \beta_2 \gg \alpha_1 β 1 ​ > β 2 ​ ≫ α 1 ​ ↑ Inotropy \uparrow\text{Inotropy} ↑ Inotropy , ↑ Chronotropy \uparrow\text{Chronotropy} ↑ Chronotropy , ↓ SVR \downarrow\text{SVR} ↓ SVR (vasodilation) 2.5 − 20 mcg/kg/min 2.5-20\text{ mcg/kg/min} 2.5 − 20 mcg/kg/min First-line inotrope for septic cardiomyopathy and persistent hypoperfusion

Angiotensin II AT 1 ≫ AT 2 \text{AT}_1 \gg \text{AT}_2 AT 1 ​ ≫ AT 2 ​ Intense vasoconstriction, aldosterone release 1.25 − 20 ng/kg/min 1.25-20\text{ ng/kg/min} 1.25 − 20 ng/kg/min ATHOS-3 (MAP response and catecholamine sparing; survival signals only in post hoc subgroups)

Phenylephrine Pure α 1 \alpha_1 α 1 ​ ↑ SVR \uparrow\text{SVR} ↑ SVR , reflex bradycardia, ↓ Stroke Volume \downarrow\text{Stroke Volume} ↓ Stroke Volume 0.1 − 2.0 mcg/kg/min 0.1-2.0\text{ mcg/kg/min} 0.1 − 2.0 mcg/kg/min Reserved strictly for severe tachyarrhythmias prohibiting other agents

Inotropic Support & Septic Cardiomyopathy

Septic shock induces acute, reversible myocardial dysfunction—termed septic cardiomyopathy —in 30% to 50% of patients. Pathophysiologically, circulating myocardial depressant factors (TNF- α \alpha α , IL- 1 β 1\beta 1 β , endotoxin) cause β \beta β -adrenergic receptor uncoupling, altered sarcoplasmic reticulum calcium handling, and mitochondrial energy starvation. Septic cardiomyopathy is characterized by biventricular dilation, impaired left or right ventricular ejection fraction, elevated cardiac filling pressures, and inadequate cardiac index.

Clinical Management with Dobutamine

The Surviving Sepsis Campaign suggests adding dobutamine to norepinephrine (starting at 2.5 mcg/kg/min 2.5\text{ mcg/kg/min} 2.5 mcg/kg/min and titrating up to 20 mcg/kg/min 20\text{ mcg/kg/min} 20 mcg/kg/min ) or using epinephrine alone in patients with:

Persistent tissue hypoperfusion (prolonged capillary refill, oliguria, hyperlactatemia, low central venous oxygen saturation [ ScvO 2 < 70 % \text{ScvO}_2 < 70\% ScvO 2 ​ < 70% ]) despite achieving MAP ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg and adequate volume resuscitation.

Objective echocardiographic evidence of left or right ventricular myocardial dysfunction.

Warning

Dobutamine stimulates vascular β 2 \beta_2 β 2 ​ receptors, which can exacerbate vasodilation and provoke sudden hypotension if initiated in hypovolemic patients or without adequate concurrent norepinephrine coverage. Pure α \alpha α -agonists like phenylephrine should be avoided in septic cardiomyopathy because excessive afterload further depresses stroke volume.

Corticosteroid Therapy: Indications and Evidence

During septic shock, patients frequently develop Critical Illness-Related Corticosteroid Insufficiency (CIRCI) , characterized by hypothalamic-pituitary-adrenal axis exhaustion, impaired tissue cortisol delivery, and cellular glucocorticoid receptor downregulation.

Surviving Sepsis Campaign Practice Statements

Indication: The 2021 guideline suggested (weak recommendation) IV corticosteroids for septic shock with an ongoing norepinephrine (or equivalent) requirement of ≥ 0.25 mcg/kg/min \ge 0.25\text{ mcg/kg/min} ≥ 0.25 mcg/kg/min for at least 4 hours . The 2026 guideline suggests IV corticosteroids for adults with septic shock (conditional recommendation) without a specific dose threshold, leaving timing to clinical judgment.

Regimen: Intravenous Hydrocortisone at a dose of 200 mg/day 200\text{ mg/day} 200 mg/day , administered either as 50 mg 50\text{ mg} 50 mg IV every 6 hours or as a continuous intravenous infusion ( 8.3 mg/hr 8.3\text{ mg/hr} 8.3 mg/hr ).

Diagnostic Testing: Do NOT perform an ACTH (cosyntropin) stimulation test or draw baseline serum cortisol levels. High-dose cosyntropin tests do not correlate with clinical outcomes and cannot distinguish patients who will benefit from steroids.

Tapering: Taper corticosteroids once vasopressors are successfully discontinued.

Synthesis of Landmark Corticosteroid Trials

Landmark Trial Sample Size & Regimen Primary Outcome Key Clinical Findings

Annane et al. (JAMA 2002) 299 patients; Hydrocortisone 50 mg 50\text{ mg} 50 mg q6h + oral Fludrocortisone 50 mcg 50\text{ mcg} 50 mcg daily for 7 days 28-day all-cause mortality Significant reduction in 28-day mortality in ACTH non-responders ( 53 % 53\% 53% vs. 63 % 63\% 63% , p = 0.02 p = 0.02 p = 0.02 ) and faster shock reversal.

CORTICUS (NEJM 2008) 499 patients; Hydrocortisone 50 mg 50\text{ mg} 50 mg q6h for 5 days, tapered over 6 days 28-day mortality in non-responders Accelerated shock reversal, but no mortality benefit ; increased rates of secondary superinfections and new hyperglycemia.

ADRENAL (NEJM 2018) 3,800 patients; Hydrocortisone continuous infusion ( 200 mg/day 200\text{ mg/day} 200 mg/day ) for 7 days 90-day all-cause mortality No significant difference in 90-day mortality ( 27.9 % 27.9\% 27.9% vs. 28.8 % 28.8\% 28.8% , p = 0.50 p = 0.50 p = 0.50 ). However, hydrocortisone significantly shortened time to shock resolution, reduced ICU length of stay, and decreased blood transfusion requirements.

APROCCHSS (NEJM 2018) 1,241 patients with severe refractory shock (norepinephrine >= 0.25 mcg/kg/min); Hydrocortisone 50 mg 50\text{ mg} 50 mg q6h + Fludrocortisone 50 mcg 50\text{ mcg} 50 mcg daily for 7 days 90-day all-cause mortality Statistically significant reduction in 90-day mortality ( 43.0 % 43.0\% 43.0% vs. 49.1 % 49.1\% 49.1% , p = 0.03 p = 0.03 p = 0.03 ), faster shock reversal, and more ventilator-free days.

Taken together, ADRENAL and APROCCHSS show consistent faster shock reversal with hydrocortisone, while mortality benefit was seen only in APROCCHSS (with fludrocortisone, in sicker patients). Meta-analyses suggest at most a small mortality benefit, which is why the recommendation is conditional rather than strong.

Albumin Administration

During septic shock, extensive shedding of the endothelial glycocalyx and systemic capillary hyperpermeability permit intravascular albumin to extravasate, precipitating hypoalbuminemia and dropping plasma colloid oncotic pressure.

Surviving Sepsis Campaign Statement: The 2021 guideline suggested albumin for patients who had received large crystalloid volumes. The 2026 guideline suggests crystalloids alone over crystalloids plus albumin (conditional recommendation).

Trial Evidence:

SAFE Trial (NEJM 2004): In a post hoc analysis of 1,218 patients with severe sepsis, resuscitation with 4% albumin was associated with lower adjusted odds of death than saline (odds ratio 0.71, 95 % CI 0.52 − 0.97 95\%\text{ CI } 0.52-0.97 95% CI 0.52 − 0.97 ); the overall SAFE trial showed no difference.

ALBIOS Trial (NEJM 2014): In 1,818 patients with severe sepsis, targeting serum albumin ≥ 30 g/L \ge 30\text{ g/L} ≥ 30 g/L with 20% albumin did not improve 90-day survival overall; a post hoc analysis of the septic shock subgroup showed lower mortality ( 43.6 % 43.6\% 43.6% vs. 49.9 % 49.9\% 49.9% ), a hypothesis-generating finding.

Caution

Hydroxyethyl starches (HES) are harmful in sepsis: the SSC recommends against them (strong recommendation) because 6S and CHEST showed more renal replacement therapy (and, in 6S, higher mortality). The SSC also suggests against gelatins (conditional recommendation).

Discredited Therapies: The Vitamin C Controversy

In 2017, a retrospective before-after single-center study by Marik and colleagues claimed that a cocktail of intravenous vitamin C (ascorbic acid), thiamine, and hydrocortisone (the "HAT" protocol) produced near-complete eradication of septic shock mortality. The biological hypothesis proposed that vitamin C scavenges free radicals, preserves endothelial barrier integrity, and acts as a cofactor for endogenous catecholamine and vasopressin synthesis.

Subsequent rigorous, double-blind multicenter randomized controlled trials thoroughly refuted this hypothesis:

CITRIS-ALI (JAMA 2019): High-dose IV vitamin C failed to improve the primary outcome of modified SOFA score or systemic inflammatory biomarkers.

VICTAS Trial (JAMA 2021): Evaluated 501 ICU patients with sepsis-induced respiratory or cardiovascular failure. The HAT protocol demonstrated no difference in ventilator- and vasopressor-free days (median 25 vs. 26 days, p = 0.85 p = 0.85 p = 0.85 ) or 30-day mortality ( 22 % 22\% 22% vs. 24 % 24\% 24% ).

Risks: High-dose parenteral vitamin C causes artifactually false high blood glucose readings on point-of-care glucometers and promotes acute calcium oxalate nephropathy.

LOVIT (NEJM 2022): In 872 ICU patients with sepsis on vasopressors, IV vitamin C (50 mg/kg every 6 hours) increased the composite of death or persistent organ dysfunction at day 28 (44.5% vs. 38.5%; risk ratio 1.21, 95% CI 1.04-1.40).

Surviving Sepsis Campaign Statement: Suggests against IV vitamin C (2021 weak recommendation; 2026 conditional recommendation). The 2026 guideline also suggests against IV immunoglobulin, blood purification, polymyxin B hemoperfusion, and vitamin D for sepsis treatment.